Cortexyme (NASDAQ:CRTX) vs. Genocea Biosciences (NASDAQ:GNCA) Head-To-Head Contrast

Insider & Institutional Ownership

63.2% of Cortexyme shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 27.9% of Cortexyme shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Cortexyme and Genocea Biosciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cortexyme	N/A	N/A	-$89.94 million	($2.97)	-0.53
Genocea Biosciences	$1.91 million	0.00	-$33.20 million	($0.61)	N/A

Genocea Biosciences has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cortexyme has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.

Profitability

This table compares Cortexyme and Genocea Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cortexyme	N/A	-70.96%	-63.53%
Genocea Biosciences	N/A	-182.88%	-62.76%

Summary

Genocea Biosciences beats Cortexyme on 6 of the 9 factors compared between the two stocks.

About Cortexyme

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.